PE20040132A1 - Metodos y formas de dosificacion para la liberacion controlada de paliperidona - Google Patents
Metodos y formas de dosificacion para la liberacion controlada de paliperidonaInfo
- Publication number
- PE20040132A1 PE20040132A1 PE2003000749A PE2003000749A PE20040132A1 PE 20040132 A1 PE20040132 A1 PE 20040132A1 PE 2003000749 A PE2003000749 A PE 2003000749A PE 2003000749 A PE2003000749 A PE 2003000749A PE 20040132 A1 PE20040132 A1 PE 20040132A1
- Authority
- PE
- Peru
- Prior art keywords
- paliperidone
- capsule
- compartment
- nucleus
- compressed
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title abstract 7
- 229960001057 paliperidone Drugs 0.000 title abstract 7
- 239000002552 dosage form Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title 1
- 239000012530 fluid Substances 0.000 abstract 4
- 239000002775 capsule Substances 0.000 abstract 3
- 239000012528 membrane Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003204 osmotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UN METODO PARA TRATAR UNA ENFERMEDAD QUE RESPONDE A LA PALIPERIDONA, QUE COMPRENDE: 1)ADMINISTRAR POR VIA ORAL UNA FORMA DE DOSIFICACION CONSISTENTE EN UN NUCLEO COMPRIMIDO, EN FORMA DE CAPSULA, CONTENIENDO PALIPERIDONA, DONDE LA FORMA DE DOSIFICACION LIBERA LA PALIPERIDONA A UNA VELOCIDAD ASCENDENTE DURANTE UN PERIODO DE TIEMPO PROLONGADO. SE REFIERE A UNA FORMA DE DOSIFICACION, QUE COMPRENDE: 1)UN NUCLEO COMPRIMIDO EN FORMA DE CAPSULA, QUE CONTIENE UNA PLURALIDAD DE CAPAS, EN DONDE LA PALIPERIDONA, ESTA CONTENIDA EN AL MENOS UNA CAPA Y AL MENOS OTRA CAPA COMPRENDE UN POLIMERO EXPANSIBLE EN UN FLUIDO ADECUADO; b)UNA MEMBRANA SEMIPERMEABLE QUE RODEA EL NUCLEO COMPRIMIDO EN FORMA DE CAPSULA PARA FORMAR UN COMPARTIMIENTO QUE TIENE UN GRADIENTE OSMOTICO PARA CONDUCIR FLUIDO DESDE UN MEDIO FLUIDO EXTERNO QUE CONTACTA LA MEMBRANA DENTRO DEL COMPARTIMIENTO; c)UN ORIFICIO FORMADO A TRAVES DE (b) Y DENTRO DE (a) PARA PERMITIR QUE LA PALIPERIDONA SEA LIBERADA DESDE EL COMPARTIMIENTO AL MEDIO FLUIDO EXTERNO; Y, d)UNA SUBCUBIERTA PARA REDUCIR LA VELOCIDAD DE DEGRADACION DE LA PALIPERIDONA, QUE COMPRENDE UN POLIMERO HIDROXIALQUILCELULOSA DE PESO MOLECULAR APROXIMADO ENTRE 8 500 A 4 500 000, QUE AL MENOS RODEA PARCIALMENTE EL NUCLEO Y ESTA POSICIONADO ENTRE UNA SUPERFICIE INTERNA DE (b) Y (a)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39959002P | 2002-07-29 | 2002-07-29 | |
| US40600502P | 2002-08-26 | 2002-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040132A1 true PE20040132A1 (es) | 2004-03-06 |
Family
ID=31191280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000749A PE20040132A1 (es) | 2002-07-29 | 2003-07-30 | Metodos y formas de dosificacion para la liberacion controlada de paliperidona |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20040092534A1 (es) |
| EP (1) | EP1539115B1 (es) |
| JP (1) | JP4500679B2 (es) |
| KR (1) | KR100699516B1 (es) |
| CN (1) | CN1684670A (es) |
| AR (1) | AR040721A1 (es) |
| AT (1) | ATE373472T1 (es) |
| AU (1) | AU2003256844A1 (es) |
| BR (1) | BR0313139A (es) |
| CA (1) | CA2494234C (es) |
| CO (1) | CO5580742A2 (es) |
| CY (1) | CY1107096T1 (es) |
| DE (1) | DE60316454T2 (es) |
| DK (1) | DK1539115T3 (es) |
| ES (1) | ES2293039T3 (es) |
| HR (1) | HRP20050077B1 (es) |
| IL (1) | IL166489A (es) |
| MX (1) | MXPA05001191A (es) |
| MY (1) | MY137049A (es) |
| NO (1) | NO324821B1 (es) |
| NZ (1) | NZ570198A (es) |
| PE (1) | PE20040132A1 (es) |
| PL (1) | PL210119B1 (es) |
| PT (1) | PT1539115E (es) |
| RU (1) | RU2321391C2 (es) |
| TW (1) | TWI363637B (es) |
| WO (1) | WO2004010981A1 (es) |
| ZA (1) | ZA200501641B (es) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050232995A1 (en) * | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| BRPI0513089B8 (pt) * | 2004-08-04 | 2021-05-25 | Alza Corp | forma de dosagem para liberação controlada de um fármaco de ordem ascendente de zero |
| US20060189635A1 (en) * | 2005-02-04 | 2006-08-24 | Michelle Kramer | Enhanced efficacy benzisoxazole derivative dosage forms and methods |
| WO2006085856A1 (en) * | 2005-02-04 | 2006-08-17 | Alza Corporation | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
| JP2009507774A (ja) * | 2005-08-04 | 2009-02-26 | アルザ・コーポレーシヨン | 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物 |
| WO2007081736A1 (en) * | 2006-01-06 | 2007-07-19 | Alza Corporation | Osmotic dosage form with controlled release and fast release aspects |
| ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
| US20070232624A1 (en) | 2006-04-03 | 2007-10-04 | Palumbo Joseph M | Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients |
| ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
| US8524749B2 (en) * | 2007-02-09 | 2013-09-03 | Alza Corporation | Controlled release compositions of tizanidine |
| HUE073014T2 (hu) * | 2007-04-25 | 2025-12-28 | Opko Renal Llc | Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén |
| KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| US20090087487A1 (en) * | 2007-08-21 | 2009-04-02 | Michael Fox | Paliperidone sustained release formulation |
| EP2081556A1 (en) | 2007-09-25 | 2009-07-29 | Teva Pharmaceutical Industries Ltd. | Stable imatinib compositions |
| KR102318070B1 (ko) * | 2007-12-19 | 2021-10-27 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| EP2280967A2 (en) * | 2008-03-27 | 2011-02-09 | Actavis Group PTC EHF | Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity |
| WO2010009900A1 (en) * | 2008-07-25 | 2010-01-28 | Krka, D.D. Novo Mesto | Paliperidone composition comprising solid matrix particles |
| EP2161019A1 (en) | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
| US20110177137A1 (en) | 2008-09-15 | 2011-07-21 | Intas Pharmaceuticals Limited | Novel dosage form of paliperidone and process for preparing the same |
| BRPI0919465A2 (pt) * | 2008-09-30 | 2015-12-01 | Endo Pharmaceuticals Solutions | dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo |
| WO2011018246A2 (en) | 2009-08-13 | 2011-02-17 | Synthon B.V. | Controlled release paliperidone composition |
| US20110052687A1 (en) * | 2009-08-26 | 2011-03-03 | Glenmark Generics Ltd | Extended release pharmaceutical composition of paliperidone |
| US20130129827A1 (en) * | 2009-10-16 | 2013-05-23 | Ranbaxy Laboratories Limited | Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof |
| EP2547206B1 (en) * | 2010-03-15 | 2016-05-11 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
| WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
| CA2796756A1 (en) * | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders |
| WO2012014052A2 (en) | 2010-07-30 | 2012-02-02 | Micro Labs Limited | Novel coated extended release pharmaceutical compositions containing paliperidone |
| CN102058517A (zh) * | 2010-12-31 | 2011-05-18 | 泰州万全医药科技有限公司 | 一种帕潘立酮缓释剂及其制备方法 |
| US20130034605A1 (en) | 2011-08-01 | 2013-02-07 | Micro Labs Limited | Extended release pharmaceutical compositions containing paliperidone |
| CN102274164B (zh) * | 2011-08-22 | 2014-07-02 | 长春健欣生物医药科技开发有限公司 | 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂 |
| KR20140146192A (ko) | 2012-04-14 | 2014-12-24 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2014102741A2 (en) * | 2012-12-28 | 2014-07-03 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
| US9708322B2 (en) | 2013-03-15 | 2017-07-18 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| CN103271889B (zh) * | 2013-05-23 | 2015-10-28 | 沈阳药科大学 | 帕利哌酮新型递增释放渗透泵制剂及其制备方法 |
| CN103385857A (zh) * | 2013-06-29 | 2013-11-13 | 北京万全德众医药生物技术有限公司 | 帕利哌酮的药物组合物 |
| WO2015001488A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Extended-release tablets of paliperidone and processes of preparation thereof |
| KR102373288B1 (ko) | 2013-12-03 | 2022-03-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| US20160000654A1 (en) * | 2014-07-07 | 2016-01-07 | Cadila Healthcare Limited | Method for determining formulation orientation of asymmetric multi-layered osmotic tablets |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| CN104257622B (zh) * | 2014-10-01 | 2020-02-07 | 浙江华海药业股份有限公司 | 一种帕利哌酮控释片及其制备方法 |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| GR1008842B (el) | 2015-08-06 | 2016-09-05 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου |
| CN105147629B (zh) * | 2015-09-24 | 2017-08-25 | 吉林大学 | 一种异丁利酮片剂及制备方法 |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| DK3407889T3 (da) | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンｄ治療法 |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3439638A1 (en) | 2016-04-05 | 2019-02-13 | Pharmathen S.A. | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |
| EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018098115A1 (en) * | 2016-11-23 | 2018-05-31 | Children's Hospital Medical Center | Paliperidone for treatment of drug refractory irritability and autism spectrum disorder |
| CN106727392A (zh) * | 2016-12-15 | 2017-05-31 | 上海奕利制药有限公司 | 一种帕利哌酮缓释片剂及其制备方法 |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| RU2767410C2 (ru) | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| EP3658144B1 (en) | 2017-07-26 | 2022-01-26 | Intra-Cellular Therapies, Inc. | Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy |
| WO2019023062A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
| US20210008065A1 (en) | 2018-03-23 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3801527B1 (en) | 2018-06-08 | 2025-02-19 | Intra-Cellular Therapies, Inc. | Fused gamma-carbolines for acute treatment of anxiety or depression |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| WO2021007245A1 (en) | 2019-07-07 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR102285510B1 (ko) | 2019-10-29 | 2021-08-04 | 강동국 | 양액 농도조절용 캡슐 및 그 용도 |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| CN113616610B (zh) * | 2021-07-30 | 2023-05-12 | 石药集团欧意药业有限公司 | 一种帕利哌酮缓释片及其制备方法 |
| WO2023220251A2 (en) * | 2022-05-12 | 2023-11-16 | Celanese Eva Performance Polymers Llc | Implantable medical device for the delivery of an antipsychotic |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| WO2024145659A1 (en) | 2022-12-30 | 2024-07-04 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor |
| WO2026011166A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor |
| WO2026011136A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656092A (en) * | 1985-10-15 | 1987-04-07 | R. P. Scherer Corporation | Target shooting capsules |
| GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| ATE398448T1 (de) * | 1993-09-28 | 2008-07-15 | Scherer Gmbh R P | Herstellung von weichgelatinekapseln |
| CN1074923C (zh) * | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| AU3909597A (en) * | 1996-08-16 | 1998-03-06 | Alza Corporation | Dosage form for providing ascending dose of drug |
| US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| ATE277594T1 (de) * | 1998-06-03 | 2004-10-15 | Alza Corp | Vorrichtungen um eine verlängerte medikamententherapie zu erreichen |
| PT1126853E (pt) * | 1998-11-02 | 2006-07-31 | Alza Corp | Distribuicao controlada de anti-depressivos |
| US6706282B1 (en) * | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
| PT1140012E (pt) * | 1998-12-17 | 2004-05-31 | Alza Corp | Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas |
| EP1169024B1 (en) * | 1999-03-31 | 2005-12-21 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| US6599532B2 (en) * | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
| US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
| US6375981B1 (en) * | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
| US6530962B1 (en) * | 2001-08-31 | 2003-03-11 | R.P. Scherer Technologies, Inc. | Emulsion of water soluble dyes in a lipophilic carrier |
-
2003
- 2003-07-28 NZ NZ570198A patent/NZ570198A/en not_active IP Right Cessation
- 2003-07-28 PL PL376258A patent/PL210119B1/pl unknown
- 2003-07-28 DK DK03771910T patent/DK1539115T3/da active
- 2003-07-28 WO PCT/US2003/023433 patent/WO2004010981A1/en not_active Ceased
- 2003-07-28 ES ES03771910T patent/ES2293039T3/es not_active Expired - Lifetime
- 2003-07-28 EP EP03771910A patent/EP1539115B1/en not_active Revoked
- 2003-07-28 KR KR1020057001460A patent/KR100699516B1/ko not_active Expired - Lifetime
- 2003-07-28 CA CA002494234A patent/CA2494234C/en not_active Expired - Lifetime
- 2003-07-28 US US10/629,211 patent/US20040092534A1/en not_active Abandoned
- 2003-07-28 JP JP2004524886A patent/JP4500679B2/ja not_active Expired - Lifetime
- 2003-07-28 RU RU2005102105/15A patent/RU2321391C2/ru not_active Application Discontinuation
- 2003-07-28 DE DE60316454T patent/DE60316454T2/de not_active Expired - Lifetime
- 2003-07-28 HR HRP20050077AA patent/HRP20050077B1/hr not_active IP Right Cessation
- 2003-07-28 BR BR0313139-4A patent/BR0313139A/pt not_active Application Discontinuation
- 2003-07-28 PT PT03771910T patent/PT1539115E/pt unknown
- 2003-07-28 AU AU2003256844A patent/AU2003256844A1/en not_active Abandoned
- 2003-07-28 MX MXPA05001191A patent/MXPA05001191A/es active IP Right Grant
- 2003-07-28 CN CNA03822948XA patent/CN1684670A/zh active Pending
- 2003-07-28 AT AT03771910T patent/ATE373472T1/de active
- 2003-07-29 TW TW092120703A patent/TWI363637B/zh not_active IP Right Cessation
- 2003-07-29 MY MYPI20032846A patent/MY137049A/en unknown
- 2003-07-29 AR AR20030102717A patent/AR040721A1/es unknown
- 2003-07-30 PE PE2003000749A patent/PE20040132A1/es not_active Application Discontinuation
-
2005
- 2005-01-25 IL IL166489A patent/IL166489A/en active IP Right Grant
- 2005-02-22 NO NO20050956A patent/NO324821B1/no not_active IP Right Cessation
- 2005-02-24 ZA ZA2005/01641A patent/ZA200501641B/en unknown
- 2005-02-28 CO CO05018509A patent/CO5580742A2/es not_active Application Discontinuation
-
2007
- 2007-12-18 CY CY20071101601T patent/CY1107096T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040132A1 (es) | Metodos y formas de dosificacion para la liberacion controlada de paliperidona | |
| Su et al. | A water-powered micro drug delivery system | |
| ES2528358T3 (es) | Aparato y procedimiento para transferir datos a un sistema de composición farmacéutica | |
| GT200000222A (es) | Forma de dosificacion de farmacos accionada por un hidrogel. | |
| ECSP088640A (es) | Método y sistema para el mantenimiento de una membrana usada para osmosis retardada con presión | |
| CO4970812A1 (es) | Sistemas de suministro osmotico, ensamble del cuerpo del sistema de suministro osmotico y sistema para controlar la tasa de suministro de agentes beneficos del sistema de suministro osmotico. | |
| PE20040131A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| AR044627A1 (es) | Dispositivo de reconstitucion y metodo para su utilizacion | |
| CY1107727T1 (el) | Οσμωτικη ενεργεια | |
| AR047698A1 (es) | Reductor de ritmo de imbibicion modular para usar con bomba osmotica implantable | |
| BRPI0919884B8 (pt) | cateter de perfusão de oclusão | |
| AR033943A1 (es) | Un dispositivo para la liberacion controlada de agentes activos a un ambiente de uso | |
| AR083524A1 (es) | Cartucho de fluido; estructura de recepcion de cartucho de fluido, dispositivo inyector de fluido, sistema de expulsion de fluido y metodo para conectar un cartucho de fluido | |
| JP2013540464A5 (es) | ||
| CO6280400A2 (es) | Inhibidores de la enzima integrasa vih y composiciones farmaceuticas que contienen dichos compuestos | |
| ATE527046T1 (de) | Verfahren zur abtrennung magnetischer partikelfraktionen durch eine semipermeable membran | |
| AR116315A1 (es) | Compuestos de triazolo-pirimidina y usos de los mismos | |
| AR063253A1 (es) | Sistema y procedimiento para detectar la posicion de una cabina de ascensor | |
| BR112012020402A2 (pt) | aparelho, sistema e método para liberar fluidos de um riser submarino | |
| CL2012002787A1 (es) | Sistema de irrigacion, en que los medios de irrigacion se pueden acomodar con mayor facilidad en un medio de crecimiento, evitando filtracion de contaminantes por la rotura o agrietamiento del sistema de irrigacion, y que comprende una membrana hidrofila tubular no porosa y helicoidal enterrada en dicho medio de crecimiento; y metodo de irrigacion | |
| CL2016000385A1 (es) | Sistema y método para separación física de partículas de diferentes tamaños y/o material dentro de una masa aglomerada en suspensión, que comprende un medio flexible de filtración selectiva y un vibrador que hace vibrar el medio flexible en ubicaciones discretas sobre la cara exterior de éste. | |
| AR241635A1 (es) | Dispositivo osmotico para la administracion de una droga a regimen de liberacion dosificado. | |
| PE20030801A1 (es) | Sistema de suministro osmotico | |
| AR089765A1 (es) | Un sistema para el suministro de un farmaco | |
| PE20050562A1 (es) | Sistema detonador y programacion de detonadores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |